• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's After-Market Session

    4/8/24 4:31:20 PM ET
    $ATRA
    $BFRI
    $BSGM
    $GRI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATRA alert in real time by email

    Gainers

    • Kineta (NASDAQ:KA) shares increased by 24.3% to $0.67 during Monday's after-market session. The market value of their outstanding shares is at $7.3 million.
    • Moleculin Biotech (NASDAQ:MBRX) stock increased by 10.21% to $5.6. The company's market cap stands at $12.4 million.
    • Cue Health (NASDAQ:HLTH) stock moved upwards by 6.01% to $0.18. The market value of their outstanding shares is at $29.3 million.
    • Nexalin Technology (NASDAQ:NXL) shares moved upwards by 5.57% to $2.46. The company's market cap stands at $18.2 million.
    • Atara Biotherapeutics (NASDAQ:ATRA) stock moved upwards by 5.52% to $0.8. The market value of their outstanding shares is at $95.2 million.
    • PetVivo Hldgs (NASDAQ:PETV) stock rose 5.26% to $1.02. The market value of their outstanding shares is at $17.1 million.

    Losers

    • BioSig Technologies (NASDAQ:BSGM) stock fell 16.9% to $1.03 during Monday's after-market session. The company's market cap stands at $9.6 million.
    • Scinai Immunotherapeutics (NASDAQ:SCNI) shares decreased by 11.92% to $0.43. The market value of their outstanding shares is at $1.8 million.
    • Processa Pharma (NASDAQ:PCSA) shares fell 5.87% to $2.81. The market value of their outstanding shares is at $4.7 million.
    • GRI Bio (NASDAQ:GRI) shares fell 4.31% to $0.52. The market value of their outstanding shares is at $1.6 million.
    • Pluri (NASDAQ:PLUR) stock fell 3.75% to $5.39. The market value of their outstanding shares is at $28.1 million.
    • Biofrontera (NASDAQ:BFRI) stock decreased by 3.54% to $1.91. The company's market cap stands at $9.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ATRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATRA
    $BFRI
    $BSGM
    $GRI

    CompanyDatePrice TargetRatingAnalyst
    Atara Biotherapeutics Inc.
    $ATRA
    1/13/2026$6.00Buy → Hold
    Canaccord Genuity
    Moleculin Biotech Inc.
    $MBRX
    6/9/2025$4.00Buy
    H.C. Wainwright
    Moleculin Biotech Inc.
    $MBRX
    2/12/2025Buy → Hold
    Maxim Group
    GRI Bio Inc.
    $GRI
    12/9/2024$10.00Buy
    H.C. Wainwright
    Processa Pharmaceuticals Inc.
    $PCSA
    4/25/2024$8.00Buy
    H.C. Wainwright
    Cue Health Inc.
    $HLTH
    3/14/2024Buy → Neutral
    BTIG Research
    Atara Biotherapeutics Inc.
    $ATRA
    11/9/2023Outperform → In-line
    Evercore ISI
    Atara Biotherapeutics Inc.
    $ATRA
    11/9/2023Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $ATRA
    $BFRI
    $BSGM
    $GRI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Atara Biotherapeutics downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Atara Biotherapeutics from Buy to Hold and set a new price target of $6.00

    1/13/26 10:16:38 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright resumed coverage on Moleculin Biotech with a new price target

    H.C. Wainwright resumed coverage of Moleculin Biotech with a rating of Buy and set a new price target of $4.00

    6/9/25 7:52:11 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Moleculin Biotech downgraded by Maxim Group

    Maxim Group downgraded Moleculin Biotech from Buy to Hold

    2/12/25 8:44:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATRA
    $BFRI
    $BSGM
    $GRI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner A.L. Sarroff Fund, Llc bought 1,250,000 shares (SEC Form 4)

    4 - PetVivo Holdings, Inc. (0001512922) (Issuer)

    3/13/26 5:10:25 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Large owner A.L. Sarroff Fund, Llc converted options into 974,809 shares and bought $77,999 worth of shares (154,840 units at $0.50) (SEC Form 4)

    4 - PetVivo Holdings, Inc. (0001512922) (Issuer)

    1/16/26 4:38:39 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Large owner A.L. Sarroff Fund, Llc bought $485,355 worth of shares (718,358 units at $0.68) and converted options into 4,033,209 shares (SEC Form 4)

    4 - PetVivo Holdings, Inc. (0001512922) (Issuer)

    1/16/26 4:38:14 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    $ATRA
    $BFRI
    $BSGM
    $GRI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration

    JERUSALEM, April 1, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI); ("Scinai" or the "Company"), a biopharmaceutical company operating a dual R&D and CDMO business model designed to combine therapeutic innovation with revenue-generating drug development and manufacturing services, today reported financial results for the year ended December 31, 2025. Corporate and Financial HighlightsCDMO revenues doubled year-over-year to $1.3 million, reflecting continued commercial traction and execution of development and manufacturing programsExpanded CDMO platform post year-end through the acquisition of Recipharm Israel and entry into a strategic commercial collaboration with Reciph

    4/1/26 7:35:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement

    HAIFA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. ("Pluri" or the "Company") (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today announced that an entity beneficially owned by Alejandro Weinstein, Chairman of the Board and one of the Company's largest shareholders, has entered into a Securities Purchase Agreement with Pluri for an additional $2.5 million investment in the Company at a 30% premium to the market price on March 24, 2026. This additional investment follows Mr. Weinstein's prior $2.5 million investment announced in connection with his appointment as Chairman of the Board, and further

    3/26/26 8:30:00 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout

    First Interim Unblinding of Pivotal AML Trial Now Imminent — Potentially the Most Important Data Moment in Company HistoryEarly Blinded Results Show 40% Remission Rate Across Difficult-to-Treat Patient PopulationEnrollment Accelerating Toward 90 Subject Threshold as Phase 3 Pathway Takes Shape HOUSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that the 45th subject has been enrolled in its pivotal Phase 2B/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adult subjects with relapsed or refractory acute myeloid leukemia (R/R AML). This milestone triggers the fin

    3/23/26 8:31:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATRA
    $BFRI
    $BSGM
    $GRI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ATRA
    $BFRI
    $BSGM
    $GRI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ATRA
    $BFRI
    $BSGM
    $GRI
    SEC Filings

    View All

    SEC Form 4 filed by Neal James R

    4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)

    4/2/26 5:12:17 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Young David

    4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)

    4/1/26 5:20:16 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Skibsted Russell

    4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)

    4/1/26 5:18:31 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 20-F filed by Scinai Immunotherapeutics Ltd.

    20-F - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

    4/1/26 7:36:13 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-3 filed by Moleculin Biotech Inc.

    S-3 - Moleculin Biotech, Inc. (0001659617) (Filer)

    3/27/26 4:01:09 PM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pluri Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Pluri Inc. (0001158780) (Filer)

    3/27/26 6:33:11 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATRA
    $BFRI
    $BSGM
    $GRI
    Leadership Updates

    Live Leadership Updates

    View All

    Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

    HOUSTON, TX, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has entered into an exclusive distribution agreement with Carmi Masha Technologies Ltd. ("Carmi Masha"), a leading Israeli medical device distributor, to market and sell Nexalin's Gen-2 Console ("SYNC"), 15 milliamp (mA), non-invasive frequency-based neurostimulation device throughout Israel. This agreement follows the recent regulatory approval by the Israeli Ministry of Health, authorizing the commercial sale of Nexalin's Gen-2 SYNC device in Israel for the treatment of a var

    11/13/25 9:15:00 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Josh Ruben Joins PetVivo Holdings, Inc. Board of Directors

    MINNEAPOLIS, MN, US, Oct. 28, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV, OTCID PETVW)), in cooperation with its wholly-owned subsidiary PetVivo Animal Health, Inc., both emerging biomedical device companies focused on the commercialization of innovative medical therapeutics for companion animals and animal athletes is pleased to announce that Josh Ruben has joined the Company's Board of Directors. "We are honored to welcome Josh Ruben to our Board of Directors," said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. "Josh brings a wealth of experience in healthcare finance, capital markets, and corporate strategy, with a proven track record of executing multi-b

    10/28/25 8:00:00 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer's and Traumatic Brain Injury Programs

    HOUSTON, TX, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the appointment of Dr. Robert Rothstein, a pioneering expert in mental healthcare, to its Scientific Advisory Board (SAB). This addition reinforces Nexalin's strategic focus on the global mental healthcare crisis, including the treatment of Alzheimer's disease and Traumatic Brain Injury (TBI). In anticipation of the Company's new FDA submissions, Dr. Rothstein will support Nexalin's preparation of its Q-submission for a meeting with the FDA later this year. Dr. Rothstein bring

    10/13/25 8:30:00 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ATRA
    $BFRI
    $BSGM
    $GRI
    Financials

    Live finance-specific insights

    View All

    Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration

    JERUSALEM, April 1, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI); ("Scinai" or the "Company"), a biopharmaceutical company operating a dual R&D and CDMO business model designed to combine therapeutic innovation with revenue-generating drug development and manufacturing services, today reported financial results for the year ended December 31, 2025. Corporate and Financial HighlightsCDMO revenues doubled year-over-year to $1.3 million, reflecting continued commercial traction and execution of development and manufacturing programsExpanded CDMO platform post year-end through the acquisition of Recipharm Israel and entry into a strategic commercial collaboration with Reciph

    4/1/26 7:35:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

    Conference call will be held today, Thursday, March 19 at 10:00 am ET Woburn, MA, March 19, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three and twelve months ended December 31, 2025 and provided a business update. Fourth Quarter Financial Highlights Revenues for 4Q25 were a record $17.1 million, a 36% increase compared to $12.6 million for the same period in 2024.Gross margins were 82.4%, a roughly 2,400 basis point year over year increase compared to 58.0% in 4Q24, reflecting the transitio

    3/19/26 9:25:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026

    Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AML HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today reported financial results for the year ended December 31, 2025 and provided a clinical update highlighting rapid progress toward a major upcoming milestone in its pivotal MIRACLE trial of Annamycin in combination with cytarabine for the treatment of adult patients with acute myeloid leukemia (AML) who are refractory to or relapsed (R/R) after induction therapy (R/R AML). "With the MIRACLE trial rapidly progressing and the first MIRACLE i

    3/19/26 8:36:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATRA
    $BFRI
    $BSGM
    $GRI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PetVivo Holdings Inc.

    SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)

    11/19/24 3:38:53 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Atara Biotherapeutics Inc.

    SC 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

    11/14/24 6:10:20 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Moleculin Biotech Inc.

    SC 13G/A - Moleculin Biotech, Inc. (0001659617) (Subject)

    11/14/24 5:12:06 PM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care